Cycling Versus Swapping in Patients with Rheumatoid Arthritis with an Inadequate Response to at Least One Tumor Necrosis Factor Alpha Inhibitor: A Systematic Review and Meta-Analysis of Observational Studies

被引:0
|
作者
Lopez-Olivo, Maria A. [1 ]
Matusevich, Aliza [1 ]
Suarez-Almazor, Maria [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Sect Rheumatol & Clin Immunol, Dept Gen Internal Med, Houston, TX 77030 USA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
2483
引用
收藏
页数:2
相关论文
共 50 条
  • [31] Meta-analysis of IL-17 inhibitors in two populations of rheumatoid arthritis patients: biologic-naive or tumor necrosis factor inhibitor inadequate responders
    Wu, Dan
    Hou, Si-Yuan
    Zhao, Shuai
    Hou, Lin-Xin
    Jiao, Ting
    Xu, Nan-Nan
    Zhang, Ning
    CLINICAL RHEUMATOLOGY, 2019, 38 (10) : 2747 - 2756
  • [32] Effect of Methotrexate, Anti-Tumor Necrosis Factor α, and Rituximab on the Immune Response to Influenza and Pneumococcal Vaccines in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
    Hua, Charlotte
    Barnetche, Thomas
    Combe, Bernard
    Morel, Jacques
    ARTHRITIS CARE & RESEARCH, 2014, 66 (07) : 1016 - 1026
  • [33] Seropositive Rheumatoid Arthritis Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors Achieve Improved Clinical Effectiveness After Switching to Rituximab Versus Switching to an Alternative Tumor Necrosis Factor Inhibitor
    Rubbert-Roth, Andrea
    Finckh, Axel
    Sarzi-Puttini, Piercarlo
    Gottenberg, Jacques-Eric
    Choquette, Denis
    Martinez Taboada, Victor
    Barile-Fabris, Leonor
    Chung, Carol
    Hinsch-Gylvin, Lykke
    Emery, Paul
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S203 - S203
  • [34] TOFACITINIB VERSUS BIOLOGIC TREATMENTS IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS A NETWORK META-ANALYSIS
    Vieira, M. C.
    Wallenstein, G.
    Bradley, J.
    Gruben, D.
    Koncz, T.
    Zwillich, S. H.
    Jansen, J. P.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 619 - 620
  • [35] Tumor Necrosis Factor-Alpha Inhibitor Use and Malignancy Risk: A Systematic Review and Patient Level Meta-Analysis
    Driscoll, Conor B.
    Rich, Jordan M.
    Isaacson, Dylan
    Nicolas, Joseph
    Jiang, Yu
    Mi, Xinlei
    Yang, Christopher
    Kocsuta, Victoria
    Goh, Regine
    Patel, Niti
    Li, Eric
    Siddiqui, Mohammad Rashid
    Meyers, Travis
    Witte, John S.
    Kachuri, Linda
    Zhang, Hui
    Beestrum, Molly
    Silberman, Philip
    Schaeffer, Edward M.
    Kundu, Shilajit D.
    CANCERS, 2025, 17 (03)
  • [36] Meta-analysis of IL-17 inhibitors in two populations of rheumatoid arthritis patients: biologic-naïve or tumor necrosis factor inhibitor inadequate responders
    Dan Wu
    Si-Yuan Hou
    Shuai Zhao
    Lin-Xin Hou
    Ting Jiao
    Nan-Nan Xu
    Ning Zhang
    Clinical Rheumatology, 2019, 38 : 2747 - 2756
  • [37] RISK OF RELAPSE AFTER DISCONTINUING TUMOR NECROSIS FACTOR INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS WITH LOW DISEASE ACTIVITY: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Filippi, N.
    Morel, J.
    Combe, B.
    Lukas, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 476 - 476
  • [38] Claims Data Analysis of Tumor Necrosis Factor Inhibitor Treatment Dosing Among Patients with Rheumatoid Arthritis: A Systematic Review of Methods
    Krack G.
    Zeidler H.
    Zeidler J.
    Drugs - Real World Outcomes, 2016, 3 (3) : 265 - 278
  • [39] Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis
    Maneiro, R. J.
    Salgado, Eva
    Carmona, Loreto
    Gomez-Reino, Juan J.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2013, 43 (01) : 9 - 17
  • [40] Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis
    Goodman, Susan M.
    Menon, Indu
    Christos, Paul J.
    Smethurst, Rie
    Bykerk, Vivian P.
    RHEUMATOLOGY, 2016, 55 (03) : 573 - 582